+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibody Fc. Linking Adaptive and Innate Immunity

  • Book

  • September 2013
  • Elsevier Science and Technology
  • ID: 2485135

Antibody Fc is the first single text to synthesize the literature on the mechanisms underlying the dramatic variability of antibodies to influence the immune response. The book demonstrates the importance of the Fc domain, including protective mechanisms, effector cell types, genetic data, and variability in Fc domain function. This volume is a critical single-source reference for researchers in vaccine discovery, immunologists, microbiologists, oncologists and protein engineers as well as graduate students in immunology and vaccinology.

Antibodies represent the correlate of protection for numerous vaccines and are the most rapidly growing class of drugs, with applications ranging from cancer and infectious disease to autoimmunity. Researchers have long understood the variable domain of antibodies, which are responsible for antigen recognition, and can provide protection by blocking the function of their target antigen. However, recent developments in our understanding of the protection mediated by antibodies have highlighted the critical nature of the antibody constant, or Fc domain, in the biological activity of antibodies. The Fc domain allows antibodies to link the adaptive and innate immune systems, providing specificity to a wide range of innate effector cells. In addition, they provide a feedback loop to regulate the character of the immune response via interactions with B cells and antigen-presenting cells.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

Part 1: Effector Mechanisms Ch 1: Antibody Dependent Cellular Cytotoxicity Ch 2: Antibody-Dependent Cellular Phagocytosis and its Impact on Pathogen Control Ch 3: Interactions between the Complement System and Fc? Receptors

Part 2: Effector Cells Ch 4: Natural Killer Cells Ch 5: Phagocytes and Immunoglobulins Ch 6: B Cells

Part 3: FcR Ch 7: Structural Recognition of Immunoglobulins by Fcg Receptors Ch 8: Fc?Rs Across Species Part 4: Variability of the Fc Domain Ch 9: Human IgG Subclasses Ch 10: Antibody Glycosylation

Part 5: Genetic Associations Ch 11: Activating and Inhibitory Fc?Rs in Autoimmune Disorders Ch 12: Fcg Receptor Polymorphisms and Susceptibility to Infection Ch 13: Role of IgG Fc Receptors in Monoclonal Antibody Therapy of Cancer

Part 6: Evolving areas Ch 14: Interactions Among Monoclonal Antibody Mechanisms of Action Ch 15: Fc Receptor-Dependent Immunity Ch 16: Fc? Receptors as Therapeutic Targets Ch 17: Fc Protein Engineering Ch 18: Bacterial Modulation of Fc Effector Functions Ch 19: Pathogenic Exploitation of Fc Activity Ch 20: Mechanisms of Immunoglobulin-Mediated Mucus Entrapment of Pathogens at Various Mucosal Surfaces

Authors

Margaret Ackerman Thayer School of Engineering, Dartmouth College
Department of Microbiology and Immunology, Geisel School of Medicine. Margaret E. Ackerman studied molecular engineering at the Massachusetts Institute of Technology under K. Dane Wittrup, followed by postdoctoral studies at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University under Galit Alter. She was appointed an Assistant Professor of Engineering at Dartmouth College's Thayer School of Engineering in 2011, and an Assistant Professor in the Department of Microbiology and Immunology at Dartmouth's Geisel School of Medicine in 2012. Her research group applies protein engineering, molecular biology, and mathematical modelling tools to design enhanced antibody therapeutics and and vaccines. Falk Nimmerjahn Institute of Genetics, Department of Biology, University of Erlangen-Nürnberg. Falk Nimmerjahn studied Biology at the Universities of Bayreuth, Erlangen-Nuernberg and Munich in Germany. After his postdoctoral studies in the laboratory of Jeffrey Ravetch at the Rockefeller University in New York from 2004-2007, he was appointed as an Associate Professor at the University Hospital of Erlangen in 2007. Since 2010 he has been a full Professor of genetics and chairman of the Institute of Genetics at the University of Erlangen-Nuernberg in the Department of Biology. His research focuses on understanding the molecular and cellular mechanisms of mouse and human IgG activity. He authored more than 80 peer reviewed papers and several chapters in text books. For his work on immunoglobulin activity he was awarded several prizes, among them the Paul-Ehrlich and Ludwig Darmstädter Award for young scientists.